Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma.

Dana PrukovaLadislav AnderaZuzana NahackaJana KarolovaMichael SvatonMagdalena KlanovaOndrej HavranekJan SoukupKarla SvobodovaZuzana ZemanovaDiana TuskovaEva PokornaKarel HelmanKristina ForsterovaMariana Pacheco-BlancoPetra VockovaAdela BerkovaEva FroňkováMarek TrnenyPavel Klener

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Our data strongly support investigation of venetoclax in combination with S63845 as an innovative treatment strategy for chemoresistant MCL patients with adverse cytogenetics in the clinical grounds.

Keyphrases

chronic lymphocytic leukemia
acute lymphoblastic leukemia
acute myeloid leukemia
diffuse large b cell lymphoma
electronic health record
multiple myeloma
hodgkin lymphoma
big data
machine learning
combination therapy
artificial intelligence
deep learning